Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

The impact of statins in combination with androgen deprivation therapyin patients with advanced prostate cancer: A large observational study.

Anderson-Carter I, Posielski N, Liou JI, Khemees TA, Downs TM, Abel EJ, Jarrard DF, Richards KA.

Urol Oncol. 2019 Feb;37(2):130-137. doi: 10.1016/j.urolonc.2018.11.017. Epub 2018 Dec 7.

PMID:
30528885
2.

Statin Use at the Time of Initiation of Androgen Deprivation Therapy and Time to Progression in Patients With Hormone-Sensitive Prostate Cancer.

Harshman LC, Wang X, Nakabayashi M, Xie W, Valenca L, Werner L, Yu Y, Kantoff AM, Sweeney CJ, Mucci LA, Pomerantz M, Lee GS, Kantoff PW.

JAMA Oncol. 2015 Jul;1(4):495-504. doi: 10.1001/jamaoncol.2015.0829. Erratum in: JAMA Oncol. 2015 Jul;1(4):544.

3.

Associations between statin use and progression in men with prostate cancer treated with primary androgen deprivation therapy.

Mikkelsen MK, Thomsen FB, Berg KD, Jarden M, Larsen SB, Hansen RB, Brasso K.

Scand J Urol. 2017 Dec;51(6):464-469. doi: 10.1080/21681805.2017.1362032. Epub 2017 Aug 23.

PMID:
28831860
4.

Improved Survival With Prostate Radiation in Addition to Androgen Deprivation Therapy for Men With Newly Diagnosed Metastatic Prostate Cancer.

Rusthoven CG, Jones BL, Flaig TW, Crawford ED, Koshy M, Sher DJ, Mahmood U, Chen RC, Chapin BF, Kavanagh BD, Pugh TJ.

J Clin Oncol. 2016 Aug 20;34(24):2835-42. doi: 10.1200/JCO.2016.67.4788. Epub 2016 Jun 20.

PMID:
27325855
5.

The impact of celecoxib on outcomes in advanced prostate cancer patients undergoing androgen deprivation therapy.

Etheridge T, Liou J, Downs TM, Abel EJ, Richards KA, Jarrard DF.

Am J Clin Exp Urol. 2018 Jun 15;6(3):123-132. eCollection 2018.

6.

Factors predicting progression to castrate-resistant prostate cancer in patients with advanced prostate cancer receiving long-term androgen-deprivation therapy.

de la Taille A, Martínez-Piñeiro L, Cabri P, Houchard A, Schalken J; Triptocare LT Study Group.

BJU Int. 2017 Jan;119(1):74-81. doi: 10.1111/bju.13455. Epub 2016 Mar 23.

7.

Statin Use and Prostate Cancer Survival in the Finnish Randomized Study of Screening for Prostate Cancer.

Murtola TJ, Peltomaa AI, Talala K, Määttänen L, Taari K, Tammela TLJ, Auvinen A.

Eur Urol Focus. 2017 Apr;3(2-3):212-220. doi: 10.1016/j.euf.2016.05.004. Epub 2016 Jun 2.

PMID:
28753762
8.

Association of Gleason Grade With Androgen Deprivation Therapy Duration and Survival Outcomes: A Systematic Review and Patient-Level Meta-analysis.

Kishan AU, Wang X, Seiferheld W, Collette L, Sandler KA, Sandler HM, Bolla M, Maingon P, De Reijke T, Hanks GE, Nickols NG, Rettig M, Drakaki A, Reiter RE, Spratt DE, Kupelian PA, Steinberg ML, King CR.

JAMA Oncol. 2019 Jan 1;5(1):91-96. doi: 10.1001/jamaoncol.2018.3732.

PMID:
30326032
9.

Androgen Deprivation Therapy and Overall Survival for Gleason 8 Versus Gleason 9-10 Prostate Cancer.

Yang DD, Mahal BA, Muralidhar V, Martin NE, Orio PF, Mouw KW, King MT, Choueiri TK, Trinh QD, Hoffman KE, Spratt DE, Feng FY, Nguyen PL.

Eur Urol. 2019 Jan;75(1):35-41. doi: 10.1016/j.eururo.2018.08.033. Epub 2018 Oct 24.

PMID:
30554605
10.

Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial.

Fizazi K, Faivre L, Lesaunier F, Delva R, Gravis G, Rolland F, Priou F, Ferrero JM, Houede N, Mourey L, Theodore C, Krakowski I, Berdah JF, Baciuchka M, Laguerre B, Fléchon A, Ravaud A, Cojean-Zelek I, Oudard S, Labourey JL, Chinet-Charrot P, Legouffe E, Lagrange JL, Linassier C, Deplanque G, Beuzeboc P, Davin JL, Martin AL, Habibian M, Laplanche A, Culine S.

Lancet Oncol. 2015 Jul;16(7):787-94. doi: 10.1016/S1470-2045(15)00011-X. Epub 2015 May 28.

PMID:
26028518
11.

Statin use and risk of prostate cancer recurrence in men treated with radiation therapy.

Gutt R, Tonlaar N, Kunnavakkam R, Karrison T, Weichselbaum RR, Liauw SL.

J Clin Oncol. 2010 Jun 1;28(16):2653-9. doi: 10.1200/JCO.2009.27.3003. Epub 2010 Apr 26.

PMID:
20421534
12.

The need for androgen deprivation therapy in patients with intermediate-risk prostate cancer treated with dose-escalated external beam radiation therapy.

Dong Y, Ruth KJ, Churilla TM, Viterbo R, Sobczak ML, Smaldone MC, Chen DY, Uzzo RG, Hallman MH, Horwitz EM.

Can J Urol. 2017 Feb;24(1):8656-8662.

PMID:
28263132
13.

Survival outcomes of Chinese metastatic prostate cancer patients following primary androgen deprivation therapy in relation to prostate-specific antigen nadir level.

Teoh JY, Tsu JH, Yuen SK, Chan SY, Chiu PK, Wong KW, Ho KL, Hou SS, Ng CF, Yiu MK.

Asia Pac J Clin Oncol. 2017 Apr;13(2):e65-e71. doi: 10.1111/ajco.12313. Epub 2014 Dec 3.

PMID:
25471685
14.

The Impact of Agent Orange Exposure on Prostate Cancer Outcomes.

Etheridge T, Liou JI, Downs TM, Abel EJ, Jarrard DF, Richards KA.

J Urol. 2019 Jan 8. doi: 10.1016/j.juro.2018.10.005. [Epub ahead of print]

PMID:
30321553
15.

Androgen deprivation therapy does not impact cause-specific or overall survival in high-risk prostate cancer managed with brachytherapy and supplemental external beam.

Merrick GS, Butler WM, Wallner KE, Galbreath RW, Allen ZA, Adamovich E, Lief J.

Int J Radiat Oncol Biol Phys. 2007 May 1;68(1):34-40. Epub 2007 Feb 7.

PMID:
17289288
16.

Duration of Androgen Deprivation Therapy Influences Outcomes for Patients Receiving Radiation Therapy Following Radical Prostatectomy.

Jackson WC, Schipper MJ, Johnson SB, Foster C, Li D, Sandler HM, Palapattu GS, Hamstra DA, Feng FY.

Eur Urol. 2016 Jan;69(1):50-7. doi: 10.1016/j.eururo.2015.05.009. Epub 2015 May 21.

PMID:
26004800
17.

Assessment of the Rate of Adherence to International Guidelines for Androgen Deprivation Therapy with External-beam Radiation Therapy: A Population-based Study.

Dell'Oglio P, Abou-Haidar H, Leyh-Bannurah SR, Tian Z, Larcher A, Gandaglia G, Fossati N, Shariat SF, Capitanio U, Briganti A, Montorsi F, Graefen M, Saad F, Karakiewicz PI.

Eur Urol. 2016 Sep;70(3):429-35. doi: 10.1016/j.eururo.2016.02.057. Epub 2016 Mar 4.

PMID:
26951945
18.

Evaluation of the effectiveness of adding androgen deprivation to modern dose-escalated radiotherapy for men with favorable intermediate-risk prostate cancer.

Falchook AD, Basak R, Mohiuddin JJ, Chen RC.

Cancer. 2016 Aug 1;122(15):2341-9. doi: 10.1002/cncr.30049. Epub 2016 May 18.

19.

Androgen Deprivation Therapy (ADT) Plus Docetaxel Versus ADT Alone in Metastatic Non castrate Prostate Cancer: Impact of Metastatic Burden and Long-term Survival Analysis of the Randomized Phase 3 GETUG-AFU15 Trial.

Gravis G, Boher JM, Joly F, Soulié M, Albiges L, Priou F, Latorzeff I, Delva R, Krakowski I, Laguerre B, Rolland F, Théodore C, Deplanque G, Ferrero JM, Culine S, Mourey L, Beuzeboc P, Habibian M, Oudard S, Fizazi K; GETUG.

Eur Urol. 2016 Aug;70(2):256-62. doi: 10.1016/j.eururo.2015.11.005. Epub 2015 Nov 21.

PMID:
26610858
20.

Taxane chemotherapy vs antiandrogen agents as first-line therapy for metastatic castration-resistant prostate cancer.

Sonpavde G, Huang A, Wang L, Baser O, Miao R.

BJU Int. 2018 Jun;121(6):871-879. doi: 10.1111/bju.14152. Epub 2018 Mar 6.

PMID:
29388324

Supplemental Content

Support Center